March 2020 Briefing - HIV & AIDSLast Updated: April 01, 2020.
Here are what the editors at HealthDay consider to be the most important developments in HIV & AIDS for March 2020. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Doctors, Hospitals, Pharmacies Warned Not to Stockpile Meds
TUESDAY, March 31, 2020 (HealthDay News) -- In a joint statement released by the American Medical Association, American Pharmacists Association, and American Society of Health-System Pharmacists, the professional groups "strongly oppose" physicians, pharmacies, and hospitals prophylactically prescribing medications or purchasing excessive amounts or stockpiles of potential treatments for COVID-19.
U.S. Army Opens Field Hospital in New York City
MONDAY, March 30, 2020 (HealthDay News) -- The first U.S. Army field hospital for civilian patients opened in New York City Monday and could be the first of many across the nation as it struggles with the coronavirus pandemic.
PPE Negative for SARS-CoV-2 After Patient Contact
FRIDAY, March 27, 2020 (HealthDay News) -- Samples collected from personal protective equipment (PPE) from health care workers (HCWs) caring for patients positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were negative for SARS-CoV-2, according to research published online March 26 in Infection Control & Hospital Epidemiology.
Workers at Risk for COVID-19 Exposure Can Access Online Training
THURSDAY, March 26, 2020 (HealthDay News) -- The National Institutes of Health has launched a new website with educational resources for hospital employees, emergency first responders, and other workers at risk for exposure to COVID-19.
Fostemsavir Active in Multidrug-Resistant HIV-1 Infection
THURSDAY, March 26, 2020 (HealthDay News) -- Among patients with multidrug-resistant HIV-1 infection who have limited therapy options, reductions in HIV-1 RNA level were significantly greater in those who received fostemsavir compared with placebo during the first eight days, according to a study published in the March 26 issue of the New England Journal of Medicine.
National Health Spending Expected to Increase Through 2028
WEDNESDAY, March 25, 2020 (HealthDay News) -- National health expenditures are projected to increase at an average annual rate of 5.4 percent for 2019 to 2028, representing almost 20 percent of U.S. gross domestic product by 2028, according to a study published online March 24 in Health Affairs.
Serial Interval of COVID-19 Estimated at 3.96 Days
FRIDAY, March 20, 2020 (HealthDay News) -- The serial interval of coronavirus 2019 (COVID-19), defined as the time between a primary case and secondary case developing symptoms, is 3.96 days, according to a study published online March 19 in Emerging Infectious Diseases, a publication of the U.S. Centers for Disease Control and Prevention.
Hep C Testing, Treatment Rates Low at Federally Qualified Health Centers
FRIDAY, March 13, 2020 (HealthDay News) -- The rates of hepatitis C virus (HCV) testing and treatment initiation are low at federally qualified health centers (FQHC) in the United States, according to a study published online March 4 in the Journal of General Internal Medicine.
Second Case of HIV-1 Cure After Stem Cell Transplant Reported
THURSDAY, March 12, 2020 (HealthDay News) -- A second case of HIV-1 cure following allogeneic hemopoietic stem cell transplantation has been reported at 30 months after analytical treatment interruption (ATI), according to a study published online March 10 in The Lancet HIV.
New HIV PrEP Drug Not Cost-Effective Compared With Generic
WEDNESDAY, March 11, 2020 (HealthDay News) -- Use of tenofovir alafenamide-emtricitabine (F/TAF) is not cost-effective compared with generic tenofovir disoproxil fumarate-emtricitabine (F/TDF) for HIV preexposure prophylaxis (PrEP) among men who have sex with men (MSM), according to a study published online March 10 in the Annals of Internal Medicine.
2018 Health Care Spending Up Due to Higher Prices
MONDAY, March 9, 2020 (HealthDay News) -- Average employer-sponsored insurance spending rose to $5,892 per person in 2018, according to the Health Care Cost Institute annual Health Care Cost and Utilization Report.
Long-Acting Cabotegravir, Rilpivirine Noninferior in HIV-1
THURSDAY, March 5, 2020 (HealthDay News) -- For patients with HIV-1 suppression, long-acting cabotegravir plus rilpivirine is noninferior to oral therapy with dolutegravir-abacavir-lamivudine and standard oral therapy, according to two studies published online March 4 in the New England Journal of Medicine.
Female Clinical Chairs Paid Significantly Less Than Men
THURSDAY, March 5, 2020 (HealthDay News) -- There are significant sex differences in salaries of clinical department chairs in public medical schools in the United States, according to a research letter published online March 2 in JAMA Internal Medicine.
Racial/Ethnic Insurance Coverage Disparity Down Since ACA
WEDNESDAY, March 4, 2020 (HealthDay News) -- Since the implementation of coverage expansions associated with the Affordable Care Act (ACA), the disparities in insurance coverage related to race and ethnicity have decreased, according to a study published in the March issue of Health Affairs.
Considerable Increase Seen in List, Net Prices of Branded Drugs
WEDNESDAY, March 4, 2020 (HealthDay News) -- From 2007 to 2018, there were substantial increases in list and net prices of branded drugs in the United States, according to a study published in the March 3 issue of the Journal of the American Medical Association.
1996 to 2016 Saw Increases in U.S. Spending on Health Care
TUESDAY, March 3, 2020 (HealthDay News) -- From 1996 to 2016, there were considerable increases in U.S. spending on health care, according to a study published in the March 3 issue of the Journal of the American Medical Association.
|Previous: March 2020 Briefing - Gastroenterology||Next: March 2020 Briefing - Infectious Disease|
Reader comments on this article are listed below. Review our comments policy.